Back to BNTXView full pipeline
Phase 3
Development Phase
0
Upcoming Catalysts
0
Historical Events
0
Regulatory Approvals
No Catalysts Found
No catalyst events have been recorded for this drug yet.
Competitive Landscape
0 competitors in Untreated Advanced or Metastatic Gastric, Gastroesophageal Junction, or Esophageal Adenocarcinoma
View Full LandscapeDrug Information
Target Indication
Untreated Advanced or Metastatic Gastric, Gastroesophageal Junction, or Esophageal Adenocarcinoma
Clinical Trial
NCT07221149Last updated: 10/21/2026
Patent & Exclusivity
No patent data available. Pre-approval drugs may not have Orange Book listings.
Drug Science
Mechanism of action & safety profile
Related Pipeline
BNT162b2 (Omi KP.2)Phase 3
SARS-CoV-2 Infection
Variant-adapted BNT162b2 (Omicron KP.2) 10 microgram dosePhase 3
SARS-CoV-2 Virus
BNT162b2 Bivalent (WT/OMI BA.1)Phase 3
SARS-CoV-2 Infection
BNT162b7 Bivalent (Original/OMI BA.4/BA.5)Phase 3
SARS-CoV-2 Infection
Variant-adapted BNT162b2 (Omicron XBB.1.5) 6 microgram dosePhase 3
SARS-CoV-2 Virus
Get Catalyst Alerts
Receive weekly digests of upcoming catalysts
